Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
ADCLEC.syn1 in People With Acute Myeloid Leukemia
What the film says
CAR T cells have not worked well in acute myeloid leukemia, for a stubborn reason: the markers on AML cells also sit on the normal stem cells that make blood. Hit one, and you risk wiping out the marrow.
The idea: require two markers before the cells fire.
At Memorial Sloan Kettering, a patient's T cells receive a deliberately weakened receptor for one AML marker, ADGRE2, and a second receptor for another, CLEC12A, that only supplies the boost. Leukemia stem cells carry both; normal blood stem cells mostly do not. In mice, the design cleared AML and prevented escape while sparing normal blood formation.
A dose-finding study in adults with relapsed or refractory AML. Jae Park leads it. Public record; not medical advice.
Sources behind this film
Haubner S. Cancer Cell, 2023
AML antigens shared with normal HSPCs → toxicity risk; Attenuated ADGRE2-CAR + CLEC12A chimeric costimulatory receptor; gated co-targeting; ADGRE2+CLEC12A+ leukemic stem cells vs ADGRE2-low CLEC12A-negative normal HSPCs; Prevents antigen escape; eradicates AML in humanized mice; HSPC toxicity comparable to CD19-CAR
Dose escalation 25–450×10⁶ flat doses; adults; Takeda collaborator; Jae Park; MSK
The drug
There are 4 planned flat-dose levels: 25 × 10^6, 75 × 10^6 , 225 × 10^6 , and 450 × 10^6 CAR T cells and 1 de-escalation dose: 10 × 10^6 CAR T cells.
Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
The study
The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this dose, it will test it in a new group of participants to see if it is effective in treating their relapsed/refractory AML.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.